PureTech Health PLC Total Liabilities
PureTech Health PLC total liabilities. Based on the latest financial reports, PureTech Health PLC (PRTC) has total liabilities worth $229.03 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PureTech Health PLC liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PureTech Health PLC (2012–2025)
Total liabilities of PureTech Health PLC from 2012 to 2025. This chart illustrates how PureTech Health PLC's total liabilities have evolved over time, based on quarterly financial data.
PureTech Health PLC Competitors by Total Liabilities
The table below lists competitors of PureTech Health PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liaoning Fu-An
SHG:603315
|
China | CN¥1.49 Billion |
|
Dalmia Bharat Sugar and Industries Limited
NSE:DALMIASUG
|
India | Rs22.86 Billion |
|
Zinzino AB Series B
ST:ZZ-B
|
Sweden | Skr1.14 Billion |
|
Jiangsu Huachen Transformer
SHG:603097
|
China | CN¥2.14 Billion |
|
Shanghai Titan Scientific Co. Ltd. A
SHG:688133
|
China | CN¥2.07 Billion |
|
InBody Co.Ltd
KQ:041830
|
Korea | ₩36.31 Billion |
|
Star Gas Partners LP
NYSE:SGU
|
USA | $621.24 Million |
|
Norma Group AG NA O.N.
XETRA:NOEJ
|
Germany | €713.83 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down PureTech Health PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PureTech Health PLC total assets.
Liquidity & Leverage Metrics
PureTech Health PLC Total Liabilities Ratios Explained
PureTech Health PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PureTech Health PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PureTech Health PLC (2012–2025)
The table below shows the annual total liabilities of PureTech Health PLC from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $229.03 Million | +17.63% |
| 2024-12-31 | $194.70 Million | -17.41% |
| 2023-12-31 | $235.74 Million | +52.03% |
| 2022-12-31 | $155.06 Million | -57.15% |
| 2021-12-31 | $361.86 Million | +7.55% |
| 2020-12-31 | $336.45 Million | +15.71% |
| 2019-12-31 | $290.78 Million | +5.82% |
| 2018-12-31 | $274.79 Million | -0.38% |
| 2017-12-31 | $275.85 Million | +33.69% |
| 2016-12-31 | $206.34 Million | +26.82% |
| 2015-12-31 | $162.70 Million | +72.46% |
| 2014-12-31 | $94.34 Million | +280.51% |
| 2013-12-31 | $24.79 Million | +10.00% |
| 2012-12-31 | $22.54 Million | -- |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more